Please ensure Javascript is enabled for purposes of website accessibility

Moderna to Start Phase 3 Clinical Trial of Its Coronavirus Vaccine Candidate in July

By Prosper Junior Bakiny – Jun 11, 2020 at 3:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech continues to race through the development of its potential SARS-CoV-2 vaccine.

Moderna (MRNA -0.37%) is currently running a phase 2 clinical trial for mRNA-1273, its investigational vaccine for SARS-CoV-2, the coronavirus that causes COVID-19. This trial will enroll 600 healthy participants, each of whom will receive two doses of the vaccine, 28 days apart. The trial is testing the vaccine's safety, reactogenicity (the dosage that begins to cause expected side effects), and immunogenicity (its ability to trigger an immune response in the body). However, while phase 2 is still underway, Moderna has already finalized the protocol for a phase 3 study of mRNA-1273, which it says will start in July. 

Moderna will collaborate with the National Institutes of Health (NIH) to conduct this phase 3 trial, which will enroll about 30,000 participants in the U.S. The primary endpoint for the trial will be "the prevention of symptomatic COVID-19 disease"; secondary endpoints include the prevention of infection by SARS-CoV-2 and the prevention of severe cases of COVID-19.

Hand drawing liquid from a glass vial with a syringe on a dark background.

Image Source: Getty Images.

Moderna's efforts to develop a vaccine for COVID-19 have been funded in part by the Biomedical Advanced Research and Development Authority (BARDA). On April 16, the company announced that it had received a grant of up to $483 million from the federal agency to help speed up the development of mRNA-1273. With further help from BARDA, Moderna is looking to manufacture up to 1 billion doses of mRNA-1273 a year starting in 2021, assuming the candidate proves effective and receives the green light from regulators. 

Moderna is already considered one of the leaders in the race to develop a vaccine for SARS-CoV-2. It was one of five pharmaceutical companies picked by the Trump administration to receive extra support as part of Operation Warp Speed, which is meant to accelerate the development of a vaccine for the deadly disease. Now that Moderna has announced its intentions to start a phase 3 clinical trial next month, the company may receive even more attention from investors. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$125.15 (-0.37%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.